Affiliation:
1. R&D center (API), Wanbury Ltd., EL-16, TTC Industrial Estate, Mahape, Navi Mumbai 400710, India
Abstract
Background:
Schiff base is an advanced key starting material of Sertraline hydrochloride.
Schiff base is synthesized using two raw materials 1-Naphthol and 1,2-Dichlorobenzene which are potentially
genotoxic impurities.
Objective:
Genotoxic impurities need to be controlled in key starting material to avoid carry forward in
the active pharmaceutical ingredient. For trace level quantification of impurities a sensitive, accurate
and cost effective method is developed by simultaneous estimation of both impurities.
Methods:
Reverse phase high performance liquid chromatography (HPLC) method was developed and
validated for determination of both impurities in Schiff base. HPLC column Cosmosil MS-II C18, 100
mm X 4.6 mm, 3 μm particle size with ultra-violet detector (UV) was used.
Results:
The calibration curve of 1-Naphthol and 1,2-Dichlorobenzene showed good linearity over the
concentration range of 0.25 µg/g to 7.5 µg/g and 1.5 µg/g to 7.5 µg/g and the regression coefficient was
0.999 and 0.998 respectively. Method had very low limit of detection (LOD) and limit of quantification
(LOQ) of both analytes which proves that the method is sensitive and suitable for quantification of
compounds at trace level.
Conclusion:
The proposed method is specific, linear, accurate, rugged and precise. Genotoxic impurities
1-Naphthol and 1,2-Dichlorobenzene are quantified and controlled in the key starting material of
Sertraline hydrochloride. The validated method can be used in quality control unit in pharmaceutical
industry.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmaceutical Science,Molecular Medicine,Biochemistry,Biophysics
Reference26 articles.
1. Veerle G.; Katleen V.S.; Damiaan D.; Dieter D.; Selective serotonin reuptake inhibitors as a novel class of immunosuppressants. Int Immunopharmacol 2014,20(1),148-156
2. Janet E.A.; Linda E.L.; Patricia A.B.; Kristan J.A.; Selective serotonin reuptake inhibitor (SSRI) antidepressants, prolactin and breast cancer. Front Oncol 2012,2,1-9
3. Pohl R.B.; Wolkow R.M.; Clary C.M.; Sertraline in the treatment of panic disorder. A double-blind multicenter trial. Am J Psychiatry 1998,155,1189-1195
4. Katzelnick D.J.; Kobak K.A.; Greist J.H.; Jefferson J.W.; Mantle J.M.; Serlin R.C.; Sertraline for social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 1995,152,1368-1371
5. Greist J.H.; Jefferson J.W.; Kobak K.A.; A one-year, double-blind, placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1995,10,57-65